Hello everyone! I am currently investigating the newer Bio-Companies in consideration of establishing both long and short positoions depending on what insight I can obtain. I wanted news on these companies prior to their becoming public. Can anyone elaborate on Polaris, and what it is about? Does Polaris hold a position in this stock, and if so, are they selling or holding onto their investment? Thanks!
http://www.genomicsontarget.com/ventureforum03.asp 4:55-5:10 Alnylam and RNA Interference Dr. John Maraganore, President, Chief Executive Officer, and Director, Alnylam Pharmaceuticals, Inc. Founded on the discovery of RNA interference, Alnylam is developing technology that can specifically and potently silence disease-causing genes. RNA interference is a natural cellular process that combats viral infections by degrading the viral genetic message before it can produce a protein. By adapting this process for therapeutic applications, any pathological gene can be "silenced" without interfering with the gene itself. Thus RNA interference represents a powerful platform of therapeutics that can treat a diverse range of human diseases. Alnylam was founded by and incubated at Polaris. Founded in 2002.